Ipamorelin EU | Buy Research-Grade Ipamorelin in Europe | ≥99% Purity

Ipamorelin is a synthetic pentapeptide and the defining selective growth hormone secretagogue receptor agonist available to laboratories across Europe — the reference GHS-R1a agonist that produces potent GH release without the prolactin, cortisol, or pronounced appetite co-secretion that confounds non-selective GH secretagogue research, making it the essential clean GH axis stimulation tool for EU research programmes requiring isolated somatotroph biology without neuroendocrine side pathway interference. Research institutions and laboratories across the EU can source verified, research-grade Ipamorelin in Europe with fast dispatch and full batch documentation included.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch Across EU & Europe | EU Peptides Stock

What Is Ipamorelin?

Ipamorelin — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — is a synthetic pentapeptide GHS-R1a agonist developed at Novo Nordisk through a systematic structure-activity relationship programme directed at a specific pharmacological objective — producing a growth hormone secretagogue with potent GHS-R1a-mediated GH release while eliminating the prolactin and cortisol co-secretion that characterises first and second generation GH secretagogues including GHRP-6 and GHRP-2. The result is a five amino acid peptide that represents the defining achievement of GHS-R1a selectivity engineering — producing GH release of comparable amplitude to GHRP-2 while prolactin and cortisol responses are reduced to negligible levels, establishing Ipamorelin as the clean GHS-R1a reference compound for all GH axis research requiring selective somatotroph stimulation without neuroendocrine co-secretion confounds.

Ipamorelin’s selectivity profile is the product of its specific structural composition — the N-terminal Aib alpha-aminoisobutyric acid residue providing DPP-IV and aminopeptidase resistance, D-2-Nal at position 3 providing the aromatic bulk required for GHS-R1a binding, and D-Phe at position 4 contributing to receptor contact geometry — producing a pentapeptide that engages GHS-R1a with high affinity and selectivity while lacking the structural elements in non-selective GH secretagogues responsible for off-target receptor activation driving prolactin and cortisol co-secretion. The C-terminal amide is essential for receptor binding affinity. Ipamorelin’s half-life of approximately two hours — extended relative to first-generation GH secretagogues through the Aib N-terminal stability enhancement — produces GH secretory responses of pharmacodynamically practical duration for pre-clinical research protocols.

Ipamorelin activates GHS-R1a through the canonical Gq/11-phospholipase C-IP3-calcium signalling pathway in pituitary somatotrophs — mobilising intracellular calcium stores and activating calcium-dependent GH granule exocytosis machinery. This Gq/11-calcium mechanism is complementary and synergistic to the Gs-cAMP-PKA pathway activated by GHRH analogues — making Ipamorelin the natural GHS-R1a pairing compound for GHRH-GHS synergy research across EU laboratories, producing synergistic GH responses from combined GHRHR and GHS-R1a co-stimulation that substantially exceed either pathway alone.

What Does Ipamorelin Do in Research?

In controlled laboratory and pre-clinical research settings across EU and European institutions, Ipamorelin is studied across selective GHS-R1a pharmacology, clean GH axis stimulation, somatotroph biology, GHRH-GHS synergy, bone biology, comparative GH secretagogue pharmacology, and as the selectivity reference for all GH secretagogue research programmes:

Selective GHS-R1a Pharmacology and Clean GH Release Research — Ipamorelin is the reference selective GHS-R1a agonist for clean GH axis stimulation research — used to characterise GHS-R1a Gq/11-calcium signal transduction in somatotroph cell models, GH release dose-response relationships under selective GHS-R1a stimulation without prolactin or cortisol co-activation, and the receptor binding characteristics distinguishing selective from non-selective GHS-R1a engagement. Research uses Ipamorelin to establish the selective GHS-R1a pharmacodynamic profile — characterising GH pulse amplitude and duration under isolated GHS-R1a stimulation, the calcium mobilisation kinetics driving GH granule exocytosis, and GHS-R1a receptor desensitisation dynamics under repeated Ipamorelin exposure. These selective GHS-R1a pharmacology studies provide the clean GH release reference dataset that is the essential starting point for all comparative GH secretagogue research across EU endocrinology and pharmacology institutions.

GH Secretagogue Selectivity Reference and Comparative Pharmacology Research — Ipamorelin’s defining selectivity profile — potent GH release with negligible prolactin and cortisol co-secretion — makes it the essential comparative reference in GH secretagogue pharmacology studies examining the selectivity consequences of structural modifications across the GH secretagogue compound library. Research employs Ipamorelin alongside GHRP-6 and GHRP-2 Acetate in parallel GH secretagogue comparison studies — characterising the GH, prolactin, and cortisol secretory profiles of each compound to establish the selectivity cost of first and second generation non-selective GHS-R1a engagement relative to Ipamorelin’s selective profile. These comparative pharmacology studies have established Ipamorelin as the selectivity benchmark that defines what clean GHS-R1a agonism looks like — providing the reference against which the off-target co-secretion biology of non-selective GH secretagogues is quantified across EU research programmes.

Somatotroph Biology and GH Secretory Reserve Research — Ipamorelin stimulation testing provides a clean GHS-R1a-specific readout of somatotroph secretory reserve — free from the prolactin and cortisol co-secretion confounds that complicate somatotroph function interpretation with non-selective GH secretagogues. Research uses Ipamorelin stimulation paradigms to characterise somatotroph GHS-R1a expression levels, Gq/11-calcium signalling capacity, and GH granule exocytosis reserve across ageing models, GH deficiency states, and pharmacological intervention studies. These somatotroph secretory reserve studies use Ipamorelin’s selectivity advantage to provide the cleanest available GHS-R1a-specific assessment of somatotroph function — complementing GHRHR stimulation testing with Sermorelin Acetate to provide a dual-pathway characterisation of somatotroph biology across EU endocrinology research programmes.

GHRH-GHS Synergy and Combined Somatotroph Pathway Research — Ipamorelin’s Gq/11-calcium mechanism is complementary to GHRH analogues’ Gs-cAMP-PKA pathway — and the synergistic GH responses from combined Ipamorelin and GHRH analogue co-administration are substantially greater than either compound alone. Research uses Ipamorelin as the selective GHS-R1a synergy component in GHRH-GHS co-stimulation studies — characterising synergistic GH response amplitudes from Ipamorelin combined with Sermorelin Acetate, Modified GRF(1-29), CJC-1295 With DAC, and Tesamorelin, the signal transduction basis of cAMP-calcium pathway complementarity in somatotrophs, and how Ipamorelin’s selectivity advantage preserves synergistic GH biology free from the prolactin and cortisol amplification that would occur with non-selective GHS-R1a synergy compounds. These GHRH-GHS synergy studies establish Ipamorelin as the preferred selective GHS-R1a partner for combined GH axis stimulation research across EU laboratories.

Bone Biology Research Without Cortisol Confound — Ipamorelin’s negligible cortisol co-secretion makes it uniquely valuable for bone biology research — cortisol’s well-characterised anti-anabolic and bone-resorbing effects would confound GH-driven anabolic bone biology interpretation with non-selective GH secretagogues that co-elevate cortisol alongside GH. Research has characterised Ipamorelin’s bone biology in rodent skeletal models — examining GH-driven growth plate chondrocyte stimulation, osteoblast activity and bone matrix synthesis changes, bone mineral density modifications, and longitudinal bone growth responses under selective GHS-R1a-driven GH secretion. The absence of cortisol co-elevation allows GH-driven anabolic bone effects to be characterised without glucocorticoid-mediated anti-anabolic interference — establishing Ipamorelin as the reference GH secretagogue for EU bone biology research requiring clean GH axis stimulation.

GH Axis Ageing and Somatopause Research — Ipamorelin’s selective GHS-R1a stimulation and practical approximately two-hour half-life make it a useful research tool for studying age-related decline in GHS-R1a-mediated somatotroph function — the component of somatopause biology attributable to reduced ghrelin axis signalling capacity as distinct from hypothalamic GHRH decline. Research has used Ipamorelin stimulation testing across aged rodent cohorts to characterise GHS-R1a-specific somatotroph reserve decline — examining peak GH response attenuation with age, GHS-R1a expression changes in aged somatotrophs, and the restoration of GH secretory responses under Ipamorelin in aged pre-clinical models. These ageing biology studies complement Sermorelin Acetate GHRHR stimulation testing to provide a comprehensive dual-pathway characterisation of somatotroph ageing biology across EU geroscience research programmes.

IGF-1 Axis Biology and Downstream Anabolic Signalling Research — Ipamorelin-driven GH release activates the downstream hepatic IGF-1 production axis — making it a research tool for studying GH-IGF-1 axis biology under selective GHS-R1a stimulation conditions free from the cortisol-driven IGF-1 suppression that would confound IGF-1 axis interpretation with non-selective GH secretagogues. Research has characterised IGF-1 axis responses to Ipamorelin-driven GH secretion — examining hepatic IGF-1 gene transcription kinetics, IGF-1 protein secretion dynamics, IGFBP-3 co-regulation, and the anabolic signalling consequences of selective GHS-R1a-driven pulsatile GH-IGF-1 axis activation. The cortisol-free GH secretory profile of Ipamorelin enables the cleanest characterisation of GH-driven IGF-1 axis biology in the GH secretagogue research compound library.

Appetite and Ghrelin Axis Biology Research — Ipamorelin produces moderate appetite stimulation through GHS-R1a engagement — less pronounced than GHRP-6 but present as a biological endpoint of GHS-R1a receptor activation. Research has characterised Ipamorelin’s appetite biology — examining GHS-R1a-mediated appetite circuit activation in hypothalamic models, the dose-response relationship between Ipamorelin GHS-R1a engagement and food intake changes in rodent feeding paradigms, and how Ipamorelin’s moderate appetite biology compares with the pronounced appetite stimulation of GHRP-6 in the GH secretagogue selectivity profile comparison. These appetite biology studies contribute to characterisation of the GHS-R1a signalling biology relevant to ghrelin axis research across EU metabolic and neuroendocrinology research institutions.

What Do Studies Say About Ipamorelin?

Research conducted across European and international institutions has produced a well-characterised and extensively replicated profile for Ipamorelin as the defining selective GHS-R1a reference compound:

Selectivity characterisation research has consistently documented Ipamorelin’s defining pharmacological profile — potent GH release with negligible prolactin and cortisol co-secretion — across rodent and primate in vivo GH secretagogue comparison studies. These selectivity studies established Ipamorelin as the clean GHS-R1a reference and provided the comparative data quantifying the prolactin and cortisol co-secretion magnitude of non-selective GH secretagogues relative to Ipamorelin’s selective profile.

GH release pharmacodynamics research has characterised Ipamorelin’s dose-dependent GH secretory responses — documenting peak GH pulse amplitude, duration, and inter-pulse interval dynamics across dose ranges relevant to pre-clinical research protocols, and establishing the pharmacodynamic profile that positions Ipamorelin between shorter-acting first-generation GH secretagogues and longer-acting MK-677 in the GH secretagogue research compound library.

GHRH-GHS synergy research has documented pronounced synergistic GH responses from Ipamorelin and GHRH analogue co-administration — characterising the cAMP-calcium complementarity mechanism, quantifying synergistic GH response amplitudes relative to individual compound responses, and establishing Ipamorelin as the preferred selective GHS-R1a synergy partner for combined somatotroph pathway stimulation research.

Bone biology research has documented Ipamorelin-driven GH-mediated anabolic skeletal effects — characterising growth plate stimulation, osteoblast activity changes, and longitudinal bone growth responses in rodent models without the cortisol-mediated anti-anabolic confounds present with non-selective GH secretagogues, establishing Ipamorelin as the reference GH secretagogue for bone biology research.

GHS-R1a receptor pharmacology research has characterised Ipamorelin’s Gq/11-calcium signal transduction — documenting calcium mobilisation kinetics, GH granule exocytosis dynamics, GHS-R1a desensitisation biology, and the receptor binding characteristics distinguishing Ipamorelin’s selective engagement from non-selective GHS-R1a agonists in comparative receptor pharmacology studies.

Ipamorelin vs Other GH Secretagogue and GH Axis Research Compounds Available in Europe

Feature	Ipamorelin	GHRP-6	GHRP-2 Acetate	MK-677	Sermorelin Acetate	CJC-1295 With DAC
Type	Synthetic pentapeptide — selective GHS-R1a agonist	Synthetic hexapeptide — non-selective GHS-R1a agonist	Synthetic hexapeptide — enhanced potency non-selective GHS-R1a	Synthetic non-peptide — oral GHS-R1a agonist	Native-sequence GHRH(1-29)NH₂ — GHRHR agonist	Tetrasubstituted GHRH(1-29) + DAC — long-acting GHRHR agonist
Receptor	GHS-R1a — selective	GHS-R1a — non-selective	GHS-R1a — non-selective	GHS-R1a — non-selective oral	GHRHR — Gs-cAMP	GHRHR — Gs-cAMP
GH Release	Potent — reference selective	Potent — reference first-gen	Enhanced potency	Sustained oral — ~24 hour	Episodic pulse — short	Sustained multi-day pulsatile
Prolactin Co-Secretion	Negligible — defining selectivity	Yes — pronounced	Yes — retained	Moderate	No	No
Cortisol Co-Secretion	Negligible — defining selectivity	Yes — pronounced	Yes — retained	Moderate	No	No
Appetite Stimulation	Moderate	Pronounced	Moderate-pronounced	Moderate	None	None
Half-Life	~2 hours	~15–60 minutes	~15–60 minutes	~24 hours — oral	~10–12 minutes	~6–8 days
Bone Biology Research	Yes — no cortisol confound	Confounded by cortisol	Confounded by cortisol	Moderate confound	No cortisol — GHRHR mechanism	No cortisol — GHRHR mechanism
Signal Transduction	Gq/11-calcium — somatotroph	Gq/11-calcium — non-selective	Gq/11-calcium — non-selective	Gq/11-calcium — oral	Gs-cAMP-PKA	Gs-cAMP-PKA
Key Research Distinction	Defining selective GHS-R1a reference — eliminates prolactin and cortisol confounds — clean GH axis stimulation benchmark	Reference first-generation non-selective GHS-R1a — prolactin + cortisol co-secretion reference	Enhanced potency non-selective — bridges GHRP-6 and Ipamorelin	Oral GHS-R1a — sustained 24-hour GH — clinical trial compound	Native-sequence GHRH physiological reference — FDA approved	Only long-acting GHRH — multi-day GH axis

Product Specifications

Parameter	Specification
Full Name	Ipamorelin
Also Known As	NNC 26-0161 / Selective GHS-R1a Agonist Pentapeptide
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Type	Synthetic Pentapeptide Selective GHS-R1a Agonist — Research Grade
Molecular Weight	711.9 Da
N-Terminal Residue	Aib — alpha-aminoisobutyric acid — DPP-IV and aminopeptidase resistance
D-Amino Acids	D-2-Nal (position 3) + D-Phe (position 4) — proteolytic resistance + GHS-R1a binding geometry
C-Terminal Amide	NH₂ — essential for GHS-R1a binding affinity
Mechanism	GHS-R1a Gq/11-PLC-IP3 → intracellular Ca²⁺ mobilisation → GH granule exocytosis — selective somatotroph stimulation
Selectivity	GH release potent / Prolactin negligible / Cortisol negligible / Appetite moderate — defining selective GHS-R1a profile
Half-Life	~2 hours — Aib N-terminal stability + D-amino acid proteolytic resistance
Key Research Distinction	Defining selective GHS-R1a reference compound — eliminates prolactin and cortisol co-secretion confounds — essential comparative control for all GH secretagogue research — preferred GHRH-GHS synergy partner
Primary Research Areas	Selective GHS-R1a pharmacology / clean GH axis stimulation / somatotroph secretory reserve / GHRH-GHS synergy / bone biology without cortisol confound / GH axis ageing / IGF-1 axis / comparative GH secretagogue pharmacology
Purity	≥99% HPLC & MS Verified
Form	Sterile Lyophilised Powder
Solubility	Sterile water or 0.1% acetic acid aqueous solution — good aqueous solubility
Storage (Powder)	-20°C, protect from light and moisture
Storage (Reconstituted)	-80°C single-use aliquots — minimise freeze-thaw cycles
Available Sizes	2mg, 5mg, 10mg
Dispatch	Fast EU & Europe dispatch
Intended Use	Research use only

Buying Ipamorelin in Europe — What’s Included

Every order of Ipamorelin dispatched across the EU and Europe includes:

✅ Batch-Specific Certificate of Analysis (CoA)

✅ HPLC Chromatogram

✅ Mass Spectrometry Confirmation — including D-amino acid configuration and C-terminal amide integrity verification

✅ Sterility & Endotoxin Testing Report

✅ Reconstitution Protocol — including comparative GH secretagogue study design guidance

✅ Technical Research Support

Frequently Asked Questions — Ipamorelin EU

Can I Buy Ipamorelin in Europe?

Yes — research-grade Ipamorelin is available to researchers and institutions across the EU and Europe with fast dispatch and full batch documentation included. Supplied strictly for laboratory research purposes only.

What Makes Ipamorelin Different from GHRP-6 and GHRP-2 for EU Research?

Ipamorelin produces potent GH release with negligible prolactin and cortisol co-secretion — GHRP-6 and GHRP-2 Acetate produce pronounced prolactin and cortisol co-elevation alongside GH release. This selectivity difference is pharmacologically critical — for any EU research application where GH biology needs to be studied in isolation from prolactin and cortisol co-secretion effects, Ipamorelin is the appropriate compound. GHRP-6 and GHRP-2 are used when studying the full non-selective GHS-R1a biological profile or when prolactin and cortisol co-secretion is itself the research subject.

Why Is Ipamorelin the Preferred GHS-R1a Compound for Bone Biology Research?

Cortisol is a potent inhibitor of bone formation — it suppresses osteoblast activity, reduces IGF-1 production, and promotes bone resorption through mechanisms that would directly confound GH-driven anabolic bone biology in research models. Non-selective GH secretagogues including GHRP-6 and GHRP-2 co-elevate cortisol alongside GH — meaning the net skeletal biology reflects the competing anabolic GH and catabolic cortisol effects simultaneously. Ipamorelin produces GH release without cortisol elevation, enabling the clean characterisation of GH-driven skeletal anabolic biology that is impossible with cortisol-co-secreting GH secretagogues.

How Does Ipamorelin Work With GHRH Analogues in Synergy Research?

Ipamorelin activates GHS-R1a through the Gq/11-calcium pathway — GHRH analogues including Sermorelin Acetate and CJC-1295 With DAC activate the GHRHR through the Gs-cAMP-PKA pathway. These two signalling mechanisms are complementary in somatotroph cells — calcium mobilisation and cAMP elevation synergise to produce GH granule exocytosis responses substantially exceeding either pathway alone. Ipamorelin is the preferred GHS-R1a partner for GHRH synergy research because its selectivity ensures the synergistic GH biology is uncontaminated by prolactin and cortisol co-secretion that would occur with non-selective GHS-R1a synergy partners.

What Is the Significance of the Aib N-Terminal Residue in Ipamorelin?

Aib — alpha-aminoisobutyric acid — at the N-terminal position of Ipamorelin provides resistance to both DPP-IV cleavage and aminopeptidase degradation that would otherwise rapidly inactivate the pentapeptide in biological environments. This N-terminal stability contribution from Aib, combined with D-amino acid proteolytic resistance at positions 3 and 4, produces Ipamorelin’s approximately two-hour half-life — substantially longer than first-generation GH secretagogues and practical for pre-clinical research protocols without requiring the modification strategies employed for much longer-acting GH axis compounds.

What Controls Are Essential for Ipamorelin Research?

Vehicle controls in matched buffer, GHS-R1a antagonist D-Lys³-GHRP-6 confirming GHS-R1a specificity of GH release, GHRP-6 at equivalent molar concentration as the non-selective GHS-R1a comparative reference establishing the prolactin and cortisol co-secretion contrast, and prolactin and cortisol endpoint measurements in all GH secretagogue comparison studies confirming Ipamorelin’s selectivity profile relative to comparator compounds. For GHRH-GHS synergy studies, individual Ipamorelin and GHRH analogue single-compound controls at matched concentrations are essential for calculating synergy ratios.

What Purity Is Required for Ipamorelin Research in Europe?

≥99% purity by HPLC and mass spectrometry is essential — D-to-L amino acid epimerisation at D-2-Nal or D-Phe positions substantially reduces GHS-R1a binding affinity and GH release potency, C-terminal de-amidation reduces receptor binding, and Aib-to-Ala substitution at position 1 restores DPP-IV sensitivity reducing circulating half-life. D-amino acid configuration verification and C-terminal amide integrity confirmation by mass spectrometry are critical specifications beyond standard sequence purity. All Ipamorelin supplied for European research is verified to ≥99% purity with D-amino acid configuration and amide integrity confirmed.

Research Disclaimer

Ipamorelin is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments across the EU and Europe. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in vitro or pre-clinical research purposes.